Trials / Completed
CompletedNCT02454478
Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)
Phase 1 Study of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic RCC
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Phase 1 study to investigate the tolerability and safety of lenvatinib in combination with Everolimus in participants with unresectable advanced or metastatic RCC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenvatinib | |
| DRUG | Everolimus |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2017-05-29
- Completion
- 2017-05-29
- First posted
- 2015-05-27
- Last updated
- 2019-03-19
- Results posted
- 2019-02-08
Locations
3 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02454478. Inclusion in this directory is not an endorsement.